Search Results

Site Search

NELL-1 [Test in Focus] - Insights

Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and...

Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services - Insights

Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to...

Test identifies Lynch syndrome for targeted cancer monitoring: Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC - Insights

Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for...

Monitoring Hurricane Milton - Insights

Hurricane Milton is approaching the west coast of Florida and is anticipated to make landfall Wednesday. We continue to monitor and track the situation with our logistics partners to minimize challenges.

Winter Storm Cora - Insights

Due to a pending winter storm affecting the FedEx hub in Memphis, Tennessee, and the UPS hub in Louisville, Kentucky, Mayo Clinic Laboratories will monitor and track the situation with our logistics partners to minimize challenges. Read...

Multigene panel provides efficient ataxia diagnosis: Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC - Insights

Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment...

Test detects autoimmune neurology disorders linked to cancer: Sean Pittock, M.D. - Insights

Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.

Autoimmune Axonal Evaluation - Insights

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on...

Whole genome sequencing streamlines diagnosis - Insights

Nicole Boczek, Ph.D., and Sarah Barnett, M.S., CGC, explain how Mayo Clinic Laboratories' whole genome sequencing provides comprehensive information for rapid diagnosis of hereditary disorders.

Addiction rehab monitoring assay - Insights

Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most...